Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Osteosarcoma

Aliases
Recurrent Osteosarcoma, Refractory Osteosarcoma, Stage IVB Osteosarcoma AJCC v7

101 clinical trials

108 products

23 drugs

Clinical trial
A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment
Status: Not yet recruiting, Estimated PCD: 2026-10-26
Product
Cabozantinib
Product
Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
Status: Recruiting, Estimated PCD: 2025-07-12
Product
Recombinant oncolytic herpes simplex virus type Ⅰ
Clinical trial
A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Fludarabine
Product
CRX100
Product
Cyclophosphamide
Product
CB-103
Clinical trial
A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway
Status: Terminated, Estimated PCD: 2022-11-11
Clinical trial
An Open-Label, Multicenter Phase 1/2 Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Status: Completed, Estimated PCD: 2023-04-25
Product
Surufatinib
Clinical trial
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2026-07-01
Product
KB707
Product
CLR 131
Clinical trial
An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
Status: Active (not recruiting), Estimated PCD: 2022-09-25
Clinical trial
Phase I/II Study of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma, and Other GD2(+) Solid Tumors
Status: Terminated, Estimated PCD: 2021-10-20
Clinical trial
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination With Gemcitabine in Adult and Pediatric Subjects With Relapsed or Refractory Osteosarcoma
Status: Active (not recruiting), Estimated PCD: 2023-08-30
Product
ZN-c3
Product
Gemcitabine
Product
3F8 Bispecific Antibody
Product
Lenvatinib
Clinical trial
Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Status: Completed, Estimated PCD: 2019-07-18
Product
Etoposide
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Ifosfamide
Clinical trial
ARTEMIS-002: A Phase 2, Multicenter, Open-label Study of Intravenous Administration of HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Status: Recruiting, Estimated PCD: 2025-12-31
Product
HS-20093
Clinical trial
Phase Ib Study to Evaluate the Efficacy, Safety and Tolerability of IBI188 Combination Therapy in Subjects With Advanced Malignancies
Status: Terminated, Estimated PCD: 2022-07-30
Product
GM-CSF
Product
Bevacizumab
Product
Pemetrexed
Product
IBI188
Product
Cisplatin/Carboplatin
Product
Sintilimab
Clinical trial
An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK510 for Patients With Osteosarcoma and Soft Tissue Sarcoma
Status: Recruiting, Estimated PCD: 2024-09-01
Product
NK510
Clinical trial
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed or Refractory Osteosarcoma (OLIE)
Status: Completed, Estimated PCD: 2022-06-22
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Product
Systemic Treatment
Clinical trial
Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Abemaciclib
Product
Copanlisib
Clinical trial
A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma
Status: Terminated, Estimated PCD: 2023-02-01
Clinical trial
Neoadjuvant Three-component Chemotherapy Based on a Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors to Increase the Response Rate Compared With Two-component Chemotherapy
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Doxorubicin
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Status: Recruiting, Estimated PCD: 2027-09-30
Product
Ensartinib
Product
Erdafitinib
Product
Larotrectinib
Product
Olaparib
Product
Palbociclib
Product
Samotolisib
Product
Selpercatinib
Product
Selumetinib
Product
Tazemetostat
Product
Tipifarnib
Product
Ulixertinib
Product
Vemurafenib
Product
Doxorubicin, Cisplatin
Clinical trial
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
Status: Completed, Estimated PCD: 2020-03-31
Drug
Dinutuximab
Drug
GM-CSF
Clinical trial
A Phase I/II Study of Natalizumab as a Single Agent in Children, Adolescents and Young Adults With Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Natalizumab
Clinical trial
Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)
Status: Recruiting, Estimated PCD: 2027-12-31
Product
T cells
Product
Pembrolizumab
Product
Nivolumab
Clinical trial
A Phase II Clinical Trial of Tucidinostat in Combination With Apatinib in Patients With Relapsed or Refractory Osteosarcoma
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
Tucidinostat
Clinical trial
A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma
Status: , Estimated PCD: 2025-03-31
Product
Trastuzumab Deruxtecan
Clinical trial
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Status: Recruiting, Estimated PCD: 2028-06-30
Drug
Tegavivint
Clinical trial
Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors
Status: Completed, Estimated PCD: 2023-10-10
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
Ivosidenib
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
A Phase I Trial of Cabozantinib (XL184) in Combination With High-dose Ifosfamide in Adults and Children With Relapsed/Refractory Ewing Sarcoma and Osteosarcoma
Status: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Product
Aldesleukin
Clinical trial
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2020-12-31
Product
Pepinemab
Clinical trial
A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Status: Recruiting, Estimated PCD: 2025-09-01
Drug
Regorafenib
Product
Placebo
Clinical trial
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
Status: Recruiting, Estimated PCD: 2026-12-31
Product
CBL0137
Clinical trial
Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Status: Completed, Estimated PCD: 2014-07-01
Product
Feraheme
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Status: Recruiting, Estimated PCD: 2024-09-30
Product
Autologous Tumor Infiltrating Lymphocytes LN-145
Product
Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Clinical trial
Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response)
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
Mifamurtide
Product
EI or M-API regimen
Drug
cyclophosphamide
Drug
fludarabine
Product
Ipilimumab
Clinical trial
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Status: Recruiting, Estimated PCD: 2024-04-28
Product
Pembrolizumab + Cabozantinib
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Zoledronate
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase I Study of Autologous Activated T-Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch Administered To Patients With Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
Status: Recruiting, Estimated PCD: 2024-06-19
Product
iC9.GD2.CAR.IL-15 T-cells
Clinical trial
A Phase II Clinical Study of Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma
Status: Not yet recruiting, Estimated PCD: 2025-02-01
Drug
Trilaciclib
Clinical trial
Phase II Multicenter Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
Status: Completed, Estimated PCD: 2019-12-31
Product
Denosumab
Clinical trial
A Prospective Phase II Clinical Trial on Pre-operative Immunotherapy and Stereotactic Body Radiotherapy Followed by Metastasectomy in Patients With Pulmonary Resectable Recurrence of Osteosarcoma
Status: Recruiting, Estimated PCD: 2026-09-15
Product
Gemcitabine + Penpulimab + Stereotactic Body Radiotherapy
Clinical trial
Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Status: Recruiting, Estimated PCD: 2025-06-01
Product
4-1BBζ EGFR806-EGFRt
Product
4-1BBζ EGFR806-EGFRt and 4-1BBζ CD19-Her2tG
Clinical trial
A Phase 2 Trial of Atezolizumab and Cabozantinib in Adolescents and Young Adults With Recurrent/Metastatic Osteosarcoma (TACOS)
Status: , Estimated PCD: 2027-12-31
Drug
Atezolizumab
Clinical trial
Maintenance Therapy With Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma After Induction Multimodal Therapy - a Phase II Multi-center Study
Status: , Estimated PCD: 2025-12-15
Product
Dinutuximab
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Status: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
A Phase 2 Study of 18F FTC 146 PET/CT in Patients With Newly Diagnosed Osteosarcoma
Status: Terminated, Estimated PCD: 2021-05-28
Product
18-F FTC 146
Clinical trial
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)
Status: Completed, Estimated PCD: 2024-04-30
Clinical trial
Evaluation of the Efficacy and Safety of Regorafenib in Patients With Refractory Primary Bone Tumors
Status: Recruiting, Estimated PCD: 2025-09-12
Clinical trial
A Phase 1/2 Study of Gemcitabine and Docetaxel in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Recurrent Osteosarcoma
Status: Active (not recruiting), Estimated PCD: 2024-09-13
Drug
Docetaxel
Drug
Gemcitabine
Product
Hydroxychloroquine
Clinical trial
Phase 2 Solid Tumor Immunotherapy Trial Using HLA-Haploidentical Transplant and Donor Natural Killer Cells: The STIR Trial
Status: Completed, Estimated PCD: 2020-06-08
Product
Donor NK Cell
Clinical trial
BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Status:
Drug
DeltaRex-G
Clinical trial
A Phase II Study of Gemcitabine-docetaxel Chemotherapy With Anti-angiogenic Therapy for Pulmonary Resectable Metastases of Osteosarcoma
Status: Active (not recruiting), Estimated PCD: 2023-11-15
Product
Apatinib
Product
GD regimen
Clinical trial
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Status: Completed, Estimated PCD: 2021-09-30
Drug
T-VEC
Clinical trial
Phase II Study Investigating the Efficacy of Neoadjuvant Dual Checkpoint Inhibition and Cryoablation Therapy in Children, Adolescents, and Young Adults With Relapsed/Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Pilot Study of Near-Infrared Imaging Using the Novel Imaging Agent Cytalux for Adolescent Patients With Metastatic Osteosarcoma Undergoing Pulmonary Metastasectomy
Status: Not yet recruiting, Estimated PCD: 2026-01-20
Product
Cytalux
Clinical trial
A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Status: Recruiting, Estimated PCD: 2026-10-01
Product
Regorafenib
Clinical trial
Phase II Trial of Olaparib in Combination With Ceralasertib in Patients With Recurrent Osteosarcoma
Status: Recruiting, Estimated PCD: 2024-06-01
Drug
Ceralasertib
Clinical trial
Phase I Clinical Study to Evaluate the Safety and Efficacy of IM83 CAR-T Cells for the Treatment of Relapsed or Refractory Osteosarcoma
Status: Not yet recruiting, Estimated PCD: 2025-06-15
Product
IM83 CAR-T Cells
Clinical trial
A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
Liposomal Irinotecan
Product
Talazoparib
Product
TMZ
Clinical trial
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Status: Recruiting, Estimated PCD: 2026-03-01
Product
MESNA
Product
B7-H3 CAR T cells
Clinical trial
Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Pediatric Solid Tumors
Status: Completed, Estimated PCD: 2023-12-27
Product
Metronomic Cyclophosphamide
Product
Thalidomide
Clinical trial
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Azacitidine
Clinical trial
A Randomized, Placebo-controlled, Double-blinded, Phase II Study of Efficacy of Regorafenib as Maintenance Treatment in Patients With High Grade Bone Sarcomas at Diagnosis or Relapse and Without Complete Remission After Standard Treatment
Status: Recruiting, Estimated PCD: 2026-07-21
Clinical trial
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
Status: Active (not recruiting), Estimated PCD: 2019-06-30
Clinical trial
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults
Status: Terminated, Estimated PCD: 2022-10-01
Product
Lyso-thermosensitive liposomal doxorubicin
Clinical trial
Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas and Neuroblastoma (VEGAS)
Status: Active (not recruiting), Estimated PCD: 2019-10-31
Product
GD2 T cells
Product
VZV vaccine
Clinical trial
A Phase I/Ib Study of Losartan in Combination With Sunitinib in the Treatment of Pediatric and Adult Patients With Relapsed or Refractory Osteosarcoma
Status: Recruiting, Estimated PCD: 2026-08-01
Drug
Losartan
Product
Sunitinib
Clinical trial
A Phase II Study of Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Phase II Multi-Arm Study to Test the Efficacy of Oleclumab and Durvalumab in Multiple Sarcoma Subtypes
Status: Recruiting, Estimated PCD: 2024-06-30
Drug
AN0025
Product
Oleclumab
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma
Status: Completed, Estimated PCD: 2014-08-01
Drug
Cisplatin
Drug
doxorubicin
Drug
etoposide
Clinical trial
A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Status: Recruiting, Estimated PCD: 2025-07-01
Product
Vactosertib
Clinical trial
MISTOSUS: Iscador® P (Mistletoe) Immunotherapy To Improve Event Free Survival In Patients With Relapsed Osteosarcoma After Resection Of Pulmonary Metastases
Status: Recruiting, Estimated PCD: 2027-05-11
Product
Iscador*P
Clinical trial
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Status: Active (not recruiting), Estimated PCD: 2024-01-26
Product
nab-Paclitaxel
Clinical trial
Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse
Status: Recruiting, Estimated PCD: 2027-07-01
Drug
Metformin
Clinical trial
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Status: Completed, Estimated PCD: 2022-05-01
Drug
Varlilumab
Clinical trial
Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
4-1BBζ B7H3-EGFRt-DHFR
Product
second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
Clinical trial
A Multicenter, Open-label, Multi-cohort Phase Ib Trial Evaluating the Efficacy and Safety of TQB2928 Injection Combined With Anlotinib Hydrochloride Capsule in Relapsed/Metastatic Osteosarcoma and Other Relapsed/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
TQB2928
Clinical trial
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL-N)
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
C7R-GD2.CART cells
Drug
mFOLFOX6
Clinical trial
GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure
Status: , Estimated PCD: 2040-12-31
Product
GD2-CAR-expressing Autologous T-lymphocytes
Clinical trial
A Phase II Trial of Avelumab, A Fully Human Antibody That Targets Cells Expressing PD-L1, in Patients With Recurrent or Progressive Osteosarcoma
Status: Completed, Estimated PCD: 2020-03-18
Product
Avelumab
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
Status: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma
Status: Active (not recruiting), Estimated PCD: 2032-12-31
Product
Magrolimab
Clinical trial
Phase II Randomized Trial of Carboplatin/Cisplatin+Pemetrexed+PD-1 Inhibitor+/- Bevacizumab in Stage IV Non-squamous NSCLC
Status: Recruiting, Estimated PCD: 2024-02-01
Product
PD-1 inhibitor
Clinical trial
Phase 1 Study of Cabozantinib in Combination With Topotecan-Cyclophosphamide for Patients With Relapsed Ewing Sarcoma or Osteosarcoma
Status: Completed, Estimated PCD: 2022-10-24
Product
Topotecan
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
Does Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Reduce Blood Loss and Transfusion Requirements? A Double-blinded Randomized Controlled Trial
Status: Completed, Estimated PCD: 2024-02-01
Product
Tranexamic acid
Product
Myeloid growth factor
Clinical trial
An Open-Label, Multi-Institutional Pilot Study to Assess the Use of Glucarpidase in Adult Patients With Osteosarcoma Receiving High-Dose Methotrexate
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Glucarpidase
Clinical trial
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Status: Completed, Estimated PCD: 2016-08-15
Product
Anti-GD2-CAR engineered T cells
Product
AP1903
Clinical trial
Methionine PET/CT Studies In Patients With Cancer
Status: Recruiting, Estimated PCD: 2027-07-27
Product
Methionine
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
Status: Active (not recruiting), Estimated PCD: 2022-06-30
Clinical trial
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-Ew) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Status: Recruiting, Estimated PCD: 2025-04-30
Product
SCRI-E2CAR_EGFRtv1
Product
UB_TT170
Clinical trial
Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Status: Recruiting, Estimated PCD: 2025-09-30
Product
CAR.70/IL15-transduced CB-derived NK cells
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Status: Active (not recruiting), Estimated PCD: 2027-09-30
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 Followed by a Randomized Controlled Trial of DFMO With or Without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Status: Not yet recruiting, Estimated PCD: 2032-07-01
Product
Difluoromethylornithine
Product
AMXT-1501